PMID- 35665671
OWN - NLM
STAT- MEDLINE
DCOM- 20220622
LR  - 20220622
IS  - 1950-6007 (Electronic)
IS  - 0753-3322 (Linking)
VI  - 152
DP  - 2022 Aug
TI  - Modulation of gut microbiota by bioactive compounds for prevention and management 
      of type 2 diabetes.
PG  - 113148
LID - S0753-3322(22)00537-6 [pii]
LID - 10.1016/j.biopha.2022.113148 [doi]
AB  - Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by 
      hyperglycemia and insulin resistance. Gut microbiota (GM) are specific groups of 
      microbes colonized in the gastrointestinal (GI) tract. They profoundly influence 
      health, disease protection, and associated with metabolic activities, and play a 
      vital role in the production of functional metabolites from dietary substances. 
      Dysbiosis of GM has been linked to the onset of T2DM and can be altered to attain 
      eubiosis by intervention with various nutritional bioactive compounds such as 
      polyphenols, prebiotics, and probiotics. This review presents an overview of the 
      evidence and underlying mechanisms by which bioactive compounds modulate the GM 
      for the prevention and management of T2DM.
CI  - Copyright (c) 2022. Published by Elsevier Masson SAS.
FAU - Sharma, Basista Rabina
AU  - Sharma BR
AD  - Department of Biochemistry, CSIR-Central Food Technological Research Institute 
      (CFTRI), KRS Road, Opp. Rail Museum, Mysuru 570020, India.
FAU - Jaiswal, Swarna
AU  - Jaiswal S
AD  - School of Food Science and Environmental Health, College of Sciences and Health, 
      Technological University Dublin - City Campus, Central Quad, Grangegorman, Dublin 
      D07 ADY7, Ireland; Environmental Sustainability and Health Institute, 
      Technological University Dublin - City Campus, Grangegorman, Dublin D07 H6K8, 
      Ireland.
FAU - Ravindra, P V
AU  - Ravindra PV
AD  - Department of Biochemistry, CSIR-Central Food Technological Research Institute 
      (CFTRI), KRS Road, Opp. Rail Museum, Mysuru 570020, India. Electronic address: 
      raviravindra1@gmail.com.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20220602
PL  - France
TA  - Biomed Pharmacother
JT  - Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
JID - 8213295
RN  - 0 (Prebiotics)
SB  - IM
MH  - *Diabetes Mellitus, Type 2/drug therapy/prevention & control
MH  - Dysbiosis
MH  - *Gastrointestinal Microbiome
MH  - Humans
MH  - Prebiotics
MH  - *Probiotics/therapeutic use
OTO - NOTNLM
OT  - Dysbiosis
OT  - Eubiosis
OT  - Gut microbiota
OT  - Type 2 diabetes
EDAT- 2022/06/07 06:00
MHDA- 2022/06/23 06:00
CRDT- 2022/06/06 14:50
PHST- 2022/01/30 00:00 [received]
PHST- 2022/05/10 00:00 [revised]
PHST- 2022/05/15 00:00 [accepted]
PHST- 2022/06/07 06:00 [pubmed]
PHST- 2022/06/23 06:00 [medline]
PHST- 2022/06/06 14:50 [entrez]
AID - S0753-3322(22)00537-6 [pii]
AID - 10.1016/j.biopha.2022.113148 [doi]
PST - ppublish
SO  - Biomed Pharmacother. 2022 Aug;152:113148. doi: 10.1016/j.biopha.2022.113148. Epub 
      2022 Jun 2.